Evaluation of cardiac toxicity of idarubicin (4-demethoxydaunorubicin)

Dexrazoxane protects against doxorubicin‐induced cardiotoxicity in susceptible human living myocardial slices: A proof‐of‐concept study

“…Nonetheless, these concerns have been discredited, and it is generally accepted that the benefits of Dex outweigh the risk of subsequent neoplasms . morphological changes and QT prolongation (Guthrie & Gibson, 1977;Kinoshita et al, 2021;Villani et al, 1988). Mirroring patterns seen in literature, we found alterations in T-, P-and R-wave morphology in both acute and chronic ECG changes following anthracycline treatment.…”

“…To identify more sensitive indicators before extensive damage sets in, we aimed to translate our novel ex vivo findings—showing a reduced excitability and heterogeneous calcium transient activation patterns in LMS exposed to Dox—into the ECGs of patients undergoing anthracycline therapy. There is limited evidence of sustained ECG changes upon Dox‐induced cardiotoxicity, with observed alterations primarily centred around T ‐wave morphological changes and QT prolongation (Guthrie & Gibson, 1977; Kinoshita et al, 2021; Villani et al, 1988). Mirroring patterns seen in literature, we found alterations in T ‐, P ‐ and R ‐wave morphology in both acute and chronic ECG changes following anthracycline treatment.…”

Dexrazoxane protects against doxorubicin‐induced cardiotoxicity in susceptible human living myocardial slices: A proof‐of‐concept study

“…Nonetheless, these concerns have been discredited, and it is generally accepted that the benefits of Dex outweigh the risk of subsequent neoplasms . morphological changes and QT prolongation (Guthrie & Gibson, 1977;Kinoshita et al, 2021;Villani et al, 1988). Mirroring patterns seen in literature, we found alterations in T-, P-and R-wave morphology in both acute and chronic ECG changes following anthracycline treatment.…”

“…To identify more sensitive indicators before extensive damage sets in, we aimed to translate our novel ex vivo findings—showing a reduced excitability and heterogeneous calcium transient activation patterns in LMS exposed to Dox—into the ECGs of patients undergoing anthracycline therapy. There is limited evidence of sustained ECG changes upon Dox‐induced cardiotoxicity, with observed alterations primarily centred around T ‐wave morphological changes and QT prolongation (Guthrie & Gibson, 1977; Kinoshita et al, 2021; Villani et al, 1988). Mirroring patterns seen in literature, we found alterations in T ‐, P ‐ and R ‐wave morphology in both acute and chronic ECG changes following anthracycline treatment.…”

Protective role of antioxidant vitamin E and catechin on idarubicin-induced cardiotoxicity in rats

“…The electron micrographs of heart muscles of general toxicity as demonstrated by a significant reduction of body weight gain and delayed manifestations of cardiac toxicity including irreversible prolongation of QT intervals, impairment of contractility of isolated myocardial preparations, and a typical pattern of morphologic alterations similar to that observed in patients treated with anthracyclines (20)(21)(22)(23)(24). Idarubicin has less toxic effects than doxorubicin and daunorubicin (25)(26)(27). In this study, idarubicin caused a decrease in body and heart weight.…”

Potential Role of Oral Anthracyclines in Older Patients with Cancer

“…No episode of congestive heart failure has been reported after oral idarubicin but the cumulative drug doses were usually low (Bertelli et al 1988;Villani et al 1989).…”

Dexrazoxane protects against doxorubicin‐induced cardiotoxicity in susceptible human living myocardial slices: A proof‐of‐concept study

“…Nonetheless, these concerns have been discredited, and it is generally accepted that the benefits of Dex outweigh the risk of subsequent neoplasms . morphological changes and QT prolongation (Guthrie & Gibson, 1977;Kinoshita et al, 2021;Villani et al, 1988). Mirroring patterns seen in literature, we found alterations in T-, P-and R-wave morphology in both acute and chronic ECG changes following anthracycline treatment.…”

“…To identify more sensitive indicators before extensive damage sets in, we aimed to translate our novel ex vivo findings—showing a reduced excitability and heterogeneous calcium transient activation patterns in LMS exposed to Dox—into the ECGs of patients undergoing anthracycline therapy. There is limited evidence of sustained ECG changes upon Dox‐induced cardiotoxicity, with observed alterations primarily centred around T ‐wave morphological changes and QT prolongation (Guthrie & Gibson, 1977; Kinoshita et al, 2021; Villani et al, 1988). Mirroring patterns seen in literature, we found alterations in T ‐, P ‐ and R ‐wave morphology in both acute and chronic ECG changes following anthracycline treatment.…”

Protective role of antioxidant vitamin E and catechin on idarubicin-induced cardiotoxicity in rats

“…The electron micrographs of heart muscles of general toxicity as demonstrated by a significant reduction of body weight gain and delayed manifestations of cardiac toxicity including irreversible prolongation of QT intervals, impairment of contractility of isolated myocardial preparations, and a typical pattern of morphologic alterations similar to that observed in patients treated with anthracyclines (20)(21)(22)(23)(24). Idarubicin has less toxic effects than doxorubicin and daunorubicin (25)(26)(27). In this study, idarubicin caused a decrease in body and heart weight.…”

Potential Role of Oral Anthracyclines in Older Patients with Cancer

“…No episode of congestive heart failure has been reported after oral idarubicin but the cumulative drug doses were usually low (Bertelli et al 1988;Villani et al 1989).…”

Dexrazoxane protects against doxorubicin‐induced cardiotoxicity in susceptible human living myocardial slices: A proof‐of‐concept study

“…Nonetheless, these concerns have been discredited, and it is generally accepted that the benefits of Dex outweigh the risk of subsequent neoplasms . morphological changes and QT prolongation (Guthrie & Gibson, 1977;Kinoshita et al, 2021;Villani et al, 1988). Mirroring patterns seen in literature, we found alterations in T-, P-and R-wave morphology in both acute and chronic ECG changes following anthracycline treatment.…”

“…To identify more sensitive indicators before extensive damage sets in, we aimed to translate our novel ex vivo findings—showing a reduced excitability and heterogeneous calcium transient activation patterns in LMS exposed to Dox—into the ECGs of patients undergoing anthracycline therapy. There is limited evidence of sustained ECG changes upon Dox‐induced cardiotoxicity, with observed alterations primarily centred around T ‐wave morphological changes and QT prolongation (Guthrie & Gibson, 1977; Kinoshita et al, 2021; Villani et al, 1988). Mirroring patterns seen in literature, we found alterations in T ‐, P ‐ and R ‐wave morphology in both acute and chronic ECG changes following anthracycline treatment.…”

Protective role of antioxidant vitamin E and catechin on idarubicin-induced cardiotoxicity in rats

“…The electron micrographs of heart muscles of general toxicity as demonstrated by a significant reduction of body weight gain and delayed manifestations of cardiac toxicity including irreversible prolongation of QT intervals, impairment of contractility of isolated myocardial preparations, and a typical pattern of morphologic alterations similar to that observed in patients treated with anthracyclines (20)(21)(22)(23)(24). Idarubicin has less toxic effects than doxorubicin and daunorubicin (25)(26)(27). In this study, idarubicin caused a decrease in body and heart weight.…”

Potential Role of Oral Anthracyclines in Older Patients with Cancer

“…No episode of congestive heart failure has been reported after oral idarubicin but the cumulative drug doses were usually low (Bertelli et al 1988;Villani et al 1989).…”